We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: immune checkpoint inhibitors
MedXY News
EnglishTag

immune checkpoint inhibitors

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Unraveling the Vascular Impact of Immune Checkpoint and VEGF Inhibitors: Insights from PET Imaging and Immune Profiling
Cardiologyarterial inflammationatherothrombosis

Unraveling the Vascular Impact of Immune Checkpoint and VEGF Inhibitors: Insights from PET Imaging and Immune Profiling

By MedXY|Sep 13, 2026

This study reveals that immune checkpoint and VEGF inhibitors, alone or combined, do not induce detectable arterial inflammation by PET, suggesting macrophage-driven plaque activation is not the main cause of related atherothrombotic events

Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer
newsimmune checkpoint inhibitors
Quad-Shot Radiotherapy

Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer

By MedXY|Aug 21, 2026

A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.

Extracellular Vesicles as Liquid Biopsy Biomarkers Predicting Immune Checkpoint Therapy Resistance in Hepatocellular Carcinoma
Gastroenterologyimmune checkpoint inhibitorsimmunotherapy resistance

Extracellular Vesicles as Liquid Biopsy Biomarkers Predicting Immune Checkpoint Therapy Resistance in Hepatocellular Carcinoma

By MedXY|Aug 9, 2026

Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and managem

MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint Inhibitors
newsimmune checkpoint inhibitorssurvival outcomes

MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint Inhibitors

By MedXY|Aug 18, 2026

This study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated with

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer
Gastroenterologycolorectal cancerimmune checkpoint inhibitors

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer

By MedXY|Jul 20, 2026

This study uncovers a novel DR5/Ligase 3 feedback mechanism that sustains immunogenicity and enhances immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer.

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes
newsimmune checkpoint inhibitorsmelanoma

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes

By MedXY|Jun 4, 2026

A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma
newsimmune checkpoint inhibitorsrecurrent vulvar cancer

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

By MedXY|Aug 18, 2026

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Targeting MLCK1 May Separate Immune Checkpoint Inhibitor Colitis From Antitumour Benefit
Gastroenterologycolitisepicatechin

Targeting MLCK1 May Separate Immune Checkpoint Inhibitor Colitis From Antitumour Benefit

By MedXY|May 20, 2026

A Gut study identifies MLCK1-driven epithelial barrier failure as a central mechanism in immune checkpoint inhibitor colitis and suggests epicatechin as a barrier-protective strategy that preserves antitumour efficacy in preclinical models.

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis
CardiologyCardio-OncologyCXCR6

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

By MedXY|Mar 11, 2026

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac in

Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events
newsimmune checkpoint inhibitorsStereotactic Radiotherapy

Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events

By MedXY|Feb 9, 2026

A prospective multicenter study of 433 patients demonstrates that combining stereotactic radiotherapy with biological cancer therapy is safe, with severe adverse events occurring in less than 10% of cases. Crucially, continuing biological t

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
Gastroenterologyantiviral prophylaxishepatocellular carcinoma

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

By MedXY|Jan 12, 2026

A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex

Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis
newsimmune checkpoint inhibitors

Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis

By MedXY|Dec 13, 2025

A patient‑level and trial‑level meta‑analysis of nine RCTs (5,114 patients) shows that adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves pathologic complete response and event‑free survival in triple‑negative breast c

Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity
CardiologyCardio-Oncologyimmune checkpoint inhibitors

Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity

By MedXY|Nov 13, 2025

An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
Neurologyimmune checkpoint inhibitorsleptomeningeal metastasis

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

By MedXY|Nov 12, 2025

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers

Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism
Dermatologydrug hypersensitivityimmune checkpoint inhibitors

Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism

By MedXY|Nov 12, 2025

A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a t

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
Gastroenterologygraft rejectionhepatocellular carcinoma

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

By MedXY|Nov 6, 2025

A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives
newsBiliary tract cancerchemotherapy

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives

By MedXY|Oct 29, 2025

Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explo

Balancing Efficacy and Safety: Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients with Advanced Cancers
Internal Medicinegraft rejectionimmune checkpoint inhibitors

Balancing Efficacy and Safety: Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients with Advanced Cancers

By MedXY|Oct 27, 2025

This systematic review and meta-analysis evaluate cancer and graft outcomes in transplant recipients treated with immune checkpoint inhibitors, revealing differences by cancer type and potential strategies to reduce rejection risk.

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives
AIartificial intelligenceimmune checkpoint inhibitors

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

By MedXY|Oct 21, 2025

AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
OncologyavelumabctDNA

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

By MedXY|Oct 7, 2025

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potentia

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities